Aardvark Therapeutics, Inc. - 8-K Filing

Aardvark Therapeutics reports Q3 2026 net loss of $19.2 million and announces FDA has lifted clinical hold on ARD-101 for Prader-Willi Syndrome. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 13, 2026, 13:18 UTC

Tickers: $AARD

Read the full article at SEC EDGAR

More Regulatory news

COMMVAULT SYSTEMS INC - 8-K Filing SEC EDGAR · November 13, 2026, 13:30 UTC
Indaptus Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 13:30 UTC
Katapult Holdings, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 13:30 UTC
GOODYEAR TIRE & RUBBER CO /OH/ - 8-K Filing SEC EDGAR · November 13, 2026, 13:30 UTC
BIO KEY INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 13, 2026, 13:30 UTC
Loop Industries, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:30 UTC
Cineverse Corp. - 10-Q Filing SEC EDGAR · November 13, 2026, 13:25 UTC
FRP HOLDINGS, INC. - 10-Q Filing SEC EDGAR · November 13, 2026, 13:22 UTC
Benitec Biopharma Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 13:22 UTC
Cineverse Corp. - 8-K Filing SEC EDGAR · November 13, 2026, 13:15 UTC